Document Detail

The current role of statin therapy in the treatment of atrial fibrillation.
MedLine Citation:
PMID:  22856623     Owner:  NLM     Status:  Publisher    
Atrial fibrillation (AF) is the most common arrhythmia and one of the major causes of morbidity and hospitalization. It is an important risk factor for thromboembolic complications and cerebrovascular disease. In AF, extensive electrical and structural remodeling of atrial tissue takes place with the main underlying mechanisms being inflammation and fibrosis. In recent years it has been shown, that beside conventional antiarrhythmic therapies, modalities aiming at reversal of atrial tissue derangement could be of some benefit in the treatment of AF. In this respect, the main focus was oriented towards drugs such as angiotensin convertase (ACE) inhibitors, angiotensin receptor blockers (ARBs), polyunsaturated fatty acids and statins. Data about the potential beneficial role of statins for AF treatment is continuously growing. It is now evident that statins act on AF mainly through their pleiotropic and not their lipid lowering properties. Several retrospective trials have shown that statins exert antiarrhythmic effects in patients with AF, while data from prospective studies are still conflicting. Thus, the definitive confirmation and explanation of statin's role in AF treatment is still missing. Herein, the current patophysiological concepts providing rationale for the use of statins in AF treatment as well as up-to-date data from retrospective and prospective clinical studies are reviewed and discussed. Particular attention is paid to various clinical settings such as primary prevention, secondary prevention (post-cardioversion) and post-operative setting. We also present our own data regarding the role of statins in prevention of the recurrence of AF after successful cardioversion.
F Naji; M Sabovic
Related Documents :
8216683 - Product notebook: a catheter anchoring device.
10745483 - Outpatient coronary angiography with 4 french catheters.
21189883 - "nil per oral after midnight": is it necessary for clear fluids?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-01
Journal Detail:
Title:  Cardiovascular & hematological agents in medicinal chemistry     Volume:  -     ISSN:  1875-6182     ISO Abbreviation:  Cardiovasc Hematol Agents Med Chem     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101266881     Medline TA:  Cardiovasc Hematol Agents Med Chem     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
University Clinical Centre, Ljubljanska st.5, 2000 Maribor, Slovenia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of retrospective calibration algorithms on hypoglycemia detection in newborn infants using co...
Next Document:  Does duration of untreated psychosis predict very long term outcome of schizophrenic disorders? resu...